Video

Keeping Momentum on the Cancer Moonshot Initiative

Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Sidney Kimmel Cancer Center, discusses plans to maintain momentum on the Cancer Moonshot initiative.

Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Sidney Kimmel Cancer Center, discusses plans to maintain momentum on the national Cancer Moonshot initiative.

The Biden Foundation established an advisory board on what the mission of the Moonshot should be, and then got to work fundraising. The fundraising will continue, and so will Biden's policy and awareness efforts, as partners such as the National Institutes of Health (NIH) and the National Cancer Institute (NCI) work to bring new treatments on to the cancer scene.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content